Blab Business
FDA Issues Warning Letter to Peptide Partners Over Unapproved Injectable Drugs
On August 24, 2026, the U.S. Food and Drug Administration sent a warning letter to Peptide Partners LLC, a Sarasota, Florida‑based company that sells research‑grade peptides. The letter, reference number 735063, cites violations of the Federal Food, Drug, and Cosmetic Act (FD&C Act) related to the sale of seven injectable products that the FDA classifies as unapproved new drugs.
The FDA’s review focused on the company’s website, https://peptide.partners/, where it lists products such as GLP‑1 S (Semaglutide), GLP‑2 T (Tirzepatide), GLP‑3 Reta (Retatrutide), SS‑31 (Elamipretide), Tesa Peptide (Tesamorelin), PT‑141 (Bremelanotide), and a Reconstitution Solution (BAC). According to the letter, the site contains statements that the products are intended for use in diagnosing, curing, or treating disease, or for affecting the structure or function of the human body. The FDA therefore considers each product a new drug under section 201(g)(1) of the FD&C Act.
Because none of the listed peptides have an active FDA approval or an approved investigational new drug application, the FDA says the company is in violation of sections 301(d) and 505(a) of the Act, which prohibit the introduction or delivery of unapproved new drugs into interstate commerce. The letter notes that the company also sells a reconstitution solution that can be used to prepare the peptides for injection, further indicating an intent to distribute injectable drugs.
Peptide Partners is required to respond within fifteen business days. The response must identify corrective actions taken to address the violations, explain steps to prevent recurrence, and include supporting documentation. The letter also invites the company to provide any information that might demonstrate the products are not in violation.
The FDA’s enforcement action is part of a broader trend. In the past two years, the agency has issued warning letters to several research‑peptide vendors, compounding pharmacies, and telehealth platforms for similar violations. The agency has emphasized that products marketed for “research use only” but containing claims that suggest therapeutic benefit are subject to the same regulatory requirements as commercial drugs.
The peptides listed in the letter are of particular interest because some have reached advanced stages of clinical development. Semaglutide and tirzepatide, for example, are approved for weight management and type 2 diabetes in the United States. Retatrutide and elamipretide are investigational agents in late‑stage trials for obesity and mitochondrial disease, respectively. Tesamorelin is approved for HIV‑associated lipodystrophy, and bremelanotide is approved for hypoactive sexual desire disorder. The FDA’s letter does not address the clinical status of the peptides beyond their approval status; it focuses solely on the lack of FDA approval for the specific product formulations sold by Peptide Partners.
The warning letter also highlights the public health risks associated with injectable drugs. The FDA notes that injectable products bypass many of the body’s natural defenses and can cause serious harm if they are not manufactured, labeled, and distributed in compliance with federal law.
Peptide Partners’ response, if forthcoming, will be closely watched by regulators, investors, and the research community. The company’s compliance status may affect its ability to continue selling peptides to researchers and could influence future regulatory scrutiny of the broader peptide market.
The FDA has made the warning letter publicly available on its website, and it remains the official record of the agency’s findings. The letter is part of the FDA’s ongoing effort to enforce the FD&C Act and protect consumers from unapproved and potentially unsafe drug products.
As of now, no enforcement action beyond the warning letter has been announced. The company’s next steps and any subsequent regulatory decisions will be reported as they become available.
The FDA’s review focused on the company’s website, https://peptide.partners/, where it lists products such as GLP‑1 S (Semaglutide), GLP‑2 T (Tirzepatide), GLP‑3 Reta (Retatrutide), SS‑31 (Elamipretide), Tesa Peptide (Tesamorelin), PT‑141 (Bremelanotide), and a Reconstitution Solution (BAC). According to the letter, the site contains statements that the products are intended for use in diagnosing, curing, or treating disease, or for affecting the structure or function of the human body. The FDA therefore considers each product a new drug under section 201(g)(1) of the FD&C Act.
Because none of the listed peptides have an active FDA approval or an approved investigational new drug application, the FDA says the company is in violation of sections 301(d) and 505(a) of the Act, which prohibit the introduction or delivery of unapproved new drugs into interstate commerce. The letter notes that the company also sells a reconstitution solution that can be used to prepare the peptides for injection, further indicating an intent to distribute injectable drugs.
Peptide Partners is required to respond within fifteen business days. The response must identify corrective actions taken to address the violations, explain steps to prevent recurrence, and include supporting documentation. The letter also invites the company to provide any information that might demonstrate the products are not in violation.
The FDA’s enforcement action is part of a broader trend. In the past two years, the agency has issued warning letters to several research‑peptide vendors, compounding pharmacies, and telehealth platforms for similar violations. The agency has emphasized that products marketed for “research use only” but containing claims that suggest therapeutic benefit are subject to the same regulatory requirements as commercial drugs.
The peptides listed in the letter are of particular interest because some have reached advanced stages of clinical development. Semaglutide and tirzepatide, for example, are approved for weight management and type 2 diabetes in the United States. Retatrutide and elamipretide are investigational agents in late‑stage trials for obesity and mitochondrial disease, respectively. Tesamorelin is approved for HIV‑associated lipodystrophy, and bremelanotide is approved for hypoactive sexual desire disorder. The FDA’s letter does not address the clinical status of the peptides beyond their approval status; it focuses solely on the lack of FDA approval for the specific product formulations sold by Peptide Partners.
The warning letter also highlights the public health risks associated with injectable drugs. The FDA notes that injectable products bypass many of the body’s natural defenses and can cause serious harm if they are not manufactured, labeled, and distributed in compliance with federal law.
Peptide Partners’ response, if forthcoming, will be closely watched by regulators, investors, and the research community. The company’s compliance status may affect its ability to continue selling peptides to researchers and could influence future regulatory scrutiny of the broader peptide market.
The FDA has made the warning letter publicly available on its website, and it remains the official record of the agency’s findings. The letter is part of the FDA’s ongoing effort to enforce the FD&C Act and protect consumers from unapproved and potentially unsafe drug products.
As of now, no enforcement action beyond the warning letter has been announced. The company’s next steps and any subsequent regulatory decisions will be reported as they become available.
